title: 10-year survival of a patient with metastatic prostate cancer: Case report and literature review.
abstract: Prostate cancer is the most common malignancy in men. The 5-year relative survival for all stages combined is 98.8%. Patients diagnosed with metastatic prostate cancer have median survival from 2 to 3 years. We describe a case of 64-year old man who clinically presented with inguinal lymphadenopathy. Because of elevated PSA levels biopsy of prostate was done and adenocarcinoma was diagnosed. Biopsy of inguinal lymph nodes confirmed the diagnosis of prostate cancer. Hormonal treatment was started and at the most recent follow-up, 10 years later, the patient is asymptomatic with no clinical signs of disseminated disease.
authors.affiliation: Department of Urology, Clinical Hospital Center Rijeka, Rijeka. kristiank@net.hr.
authors.forename: Kristian
authors.initials: K
authors.lastname: Krpina
authors.forename: Dean
authors.initials: D
authors.lastname: Markić
authors.forename: Dražen
authors.initials: D
authors.lastname: Rahelić
authors.forename: Juraj
authors.initials: J
authors.lastname: Ahel
authors.forename: Nino
authors.initials: N
authors.lastname: Rubinić
authors.forename: Josip
authors.initials: J
authors.lastname: Španjol
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary* / Q000628:therapy*; D000726:Androgen Antagonists / Q000627:therapeutic use*; D044963:Biopsy, Fine-Needle / Q000379:methods; D003937:Diagnosis, Differential; D006801:Humans; D007264:Inguinal Canal; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy*; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists